Artículos SCI

Different Cu@Pd-TiO2 systems have been prepared by a two-step synthesis to obtain a bimetallic co-catalyst for the H-2 photoreforming reaction. We find that the tailored deposition of Pd covering the Cu nanoclusters by a galvanic replacement process results in the formation of a core@shell structure. The photocatalytic H-2 production after 18 h is 350 mmol/g on the Cu@Pd-1.0-TiO2 bimetallic system, which is higher than that on the monometallic ones with a H-2 production of 250 mmol/g on Pd-supported TiO2. Surface characterization by highangle annular dark-field scanning transmission electron microscopy, H-2-temperatureprogramed reduction, CO-FTIR spectroscopy, and XPS gives clear evidence of the formation of a core@shell structure. With a Pd loading of 0.2-0.3 at. %, we propose a full coverage of the Cu nanoparticles with Pd. Long-time photoreforming runs show the enhanced performance of supported Cu@Pd with respect to bare palladium leading to a more stable catalyst and ultimately higher H-2 production.

Malignancies such as lung, breast and pancreatic carcinomas are associated with increased expression of the epidermal growth factor receptor, EGFR, and its role in the pathogenesis and progression of tumors has made this receptor a prime target in the development of antitumor therapies. In therapies targeting EGFR, the development of resistance owing to mutations and single nucleotide polymorphisms, and the expression of the receptor ligands themselves are very serious issues. In this work, both the ligand neuregulin and a bispecific antibody fragment to EGFR are conjugated separately or together to the same drug-delivery system to find the most promising candidate. Camptothecin is used as a model chemotherapeutic drug and superparamagnetic iron oxide nanoparticles as a delivery system. Results show that the lowest LD50 is achieved by formulations conjugated to both the antibody and the ligand, demonstrating a synergy. Additionally, the ligand location in the nucleus favors the antitumor activity of Camptothecin. The high loading capacity and efficiency convert these systems into a good alternative for administering Camptothecin, a drug whose use is otherwise severely limited by its chemical instability and poor solubility. Our choice of targeting agents allows treating tumors that express ErbB2 (Her2+ tumors) as well as Her2- tumors expressing EGFR.